• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Diabetes - Articles and news items

GeNeuro initiates Phase 2a study in Australia to treat Type 1 Diabetes

Industry news / 19 April 2017 / Niamh Marriott, Junior Editor

GeNeuro have started a Phase 2a clinical study in Australia with GNbAC1 in patients with Type 1 diabetes. GNbAC1 is a monoclonal antibody designed to…

2017 Pipelines: Drugs to watch

Blog, Z Homepage promo / 12 April 2017 / Alexandra Kibble, Senior Editor, Clarivate Analytics Cortellis

The annual Drugs to Watch report forecasts that eight new drugs will enter the market in 2017 and achieve blockbuster sales of >$900 billion by 2021…

EU approval for Sanofi’s type 2 diabetes treatment

Industry news / 19 January 2017 / Niamh Marriott, Digital Editor

Suliqua is an innovative new combination therapy that has the potential to address significant unmet needs for people living with type 2 diabetes in Europe

FDA to review 3 new diabetes drugs that reduce cardiovascular death risk

Industry news / 5 January 2017 / Niamh Marriott, Digital Editor

In the trial, empagliflozin significantly reduced the relative risk of the combined primary endpoint of cardiovascular death, non-fatal heart attack by 14%…

Sanofi’s insulin injection Soliqua 100/33 now available in US

Industry news / 4 January 2017 / Niamh Louise Marriott, Digital Editor

It is indicated for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin (less than 60 Units daily) or lixisenatide…

FDA approval for Sanofi’s Soliqua to treat type 2 Diabetes

Industry news / 29 November 2016 / Niamh Louise Marriott, Digital Editor

Soliqua 100/33 is the combination of Lantus (insulin glargine 100 Units/mL) and lixisenatide, a GLP-1 receptor agonist, studied in a Phase 3 program…

Post-meal hyperglycaemia has negative impact on diabetic quality of life

Industry news / 4 November 2016 / Niamh Louise Marriott, Digital Content Producer

New data from a study related to post-meal or postprandial glucose control, show that poor PPG control has a negative impact on diabetics quality of life…

NICE plans to recommend extra ‘triple therapy’ type 2 diabetes drug

Industry news / 7 October 2016 / Niamh Louise Marriott, Digital Content Producer

Once final guidance is published, dapagliflozin will join two other similar drugs, empagliflozin and canagliflozin, as options for triple therapy…

Novartis’ global study shows 57% of psoriasis patients didn’t reach clear skin treatment goal

Industry news / 3 October 2016 / Niamh Louise Marriott, Digital Content Producer

People with the autoimmune disease, psoriasis, also report that they face discrimination, humiliation, and mental illness…

Social media sourced Real World Evidence: A new wave in collecting data

Blog, Z Homepage promo / 3 October 2016 / Peter Brady, CEO Orbital Media and Dr Martin Goldman, independent medical officer, Iatros Consulting

Dr Martin Goldman joins Peter Brady, Orbital Media’s CEO, to discuss how to untap the potential of social media sourced real world evidence…

Novo Nordisk’s semaglutide reduced major cardiovascular events in 1 in 4 type 2 diabetic adults

Industry news / 21 September 2016 / Niamh Louise Marriott, Digital Content Producer

Fewer serious adverse events were seen with semaglutide vs placebo; however, treatment discontinuation due to adverse events was more frequent…

Gelesis appoints new Chief Operating Officer in anticipation of obesity product launch

Industry news / 6 September 2016 / Niamh Louise Marriott, Digital Content Producer

Gelesis, a biotechnology company focused on developing products to safely induce weight loss and improve glycaemic control, have appointed David Pass, PhD as Chief Operating Officer…